Drug class in one race
CTLA-4 drugs for Non-Small Cell Lung Cancer
4 tracked CTLA-4 drugs in the Non-Small Cell Lung Cancer race. The class explanation lives on the CTLA-4 page; the full indication pipeline across every mechanism is on the Non-Small Cell Lung Cancer page.
1 approved / phase 41 Phase 31 Phase 21 Phase 1/2
Head-to-head evidence: BA3071 vs Tremelimumab · Botensilimab vs Tremelimumab · Gotistobart vs Tremelimumab